On April 27, 2026, Veradermics, Inc. disclosed that its experimental oral hair-loss drug VDPHL01 hit the primary efficacy endpoint in Study 302, a late-stage, placebo-controlled trial enrolling men ...

Phase 2/3 trial data show VDPHL01, an oral non-hormonal extended-release minoxidil, improves hair growth and patient-reported outcomes in male pattern hair loss.

This treatment is now in late-stage testing ahead of potential FDA review. New oral hair loss pill in phase 3 trials shows promising regrowth results. VDPHL01 pill is an extended-release version of ...

Hair loss has long confounded the pharmaceutical industry, but there’s hope on the horizon. Veradermics has announced success in its late-stage clinical trial with a drug to reverse hair loss. The ...

Hair loss is a widespread problem in the US, with roughly 50 million men and 30 million women experiencing pattern baldness.

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. Navigating male hair loss can be tricky, especially given the ...

Veradermics’ experimental oral minoxidil pill, VDPHL01, has delivered strong results in late-stage trials for male pattern baldness, with up to 86% of participants reporting improved hair coverage.

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release ...

Hair loss can be frustrating for most because it’s often hard to manage. It’s no surprise that more people are turning to ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.